| 产品名称 | KRCA 0008 |
| 产品货号 | Axon 2294 CAS [1472795-20-2] MF C30H37ClN8O4MW 609.12 Purity: 100% Soluble in DMSO Description Potent and selective dual ALK (anaplastic lymphoma kinase ) and ACK1 inhibitor (IC50 values 12 nM and 4 nM for ALK and Ack1, respectively) with good drug-like properties: good water-solubility with moderate plasma protein binding and low brain exposure. It has good liver microsomal stability and little to no CYP inhibition. KRCA0008 also shows promising pharmacokinetic parameters in both mice and rat (oral bioavailability = 66-94.5%) and a modest tumor growth inhibition in vivo activity in H3122 human lung cancer bearing mice model comparable to Crizotinib (Axon 1660) without significant body weight change. References Certificates Categories Extra info C.H. Park et al. Novel bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines (KRCA-0008) as potent and selective ALK inhibitors for anticancer treatment. Bioorg Med Chem Lett. 2013 Nov 15;23(22):6192-6. H.J. Lee et al. ALK inhibitors of bis-ortho-alkoxy-para-piperazinesubstituted-pyrimidines and -triazines for cancer treatment. Arch Pharm Res. 2014 Sep;37(9):1130-8. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology Endocrinology ACK1 TGF-β EC 2.7.10.1 ALK ALK Potent and selective dual ALK/ACK1 inhibitor with good drug-like properties Chemical name 1,1'-(4,4'-(4,4'-(5-chloropyrimidine-2,4-diyl)bis(azanediyl)bis(3-methoxy-4,1-phenylene))bis(piperazine-4,1-diyl))diethanone Parent CAS No. [1472795-20-2] Order Size Unit Price Stock 5 mg €95.00 In Stock |
| 产品价格 | 现货询价，电话：010-67529703 |
| 产品规格 | |
| 产品品牌 | axonmedchem |
| 产品概述 | |
| 产品详情 |
KRCA 0008Axon 2294 CAS [1472795-20-2] MF C30H37ClN8O4
DescriptionPotent and selective dual ALK (anaplastic lymphoma kinase ) and ACK1 inhibitor (IC50 values 12 nM and 4 nM for ALK and Ack1, respectively) with good drug-like properties: good water-solubility with moderate plasma protein binding and low brain exposure. It has good liver microsomal stability and little to no CYP inhibition. KRCA0008 also shows promising pharmacokinetic parameters in both mice and rat (oral bioavailability = 66-94.5%) and a modest tumor growth inhibition in vivo activity in H3122 human lung cancer bearing mice model comparable to Crizotinib (Axon 1660) without significant body weight change.
Potent and selective dual ALK/ACK1 inhibitor with good drug-like properties
Chemical name1,1'-(4,4'-(4,4'-(5-chloropyrimidine-2,4-diyl)bis(azanediyl)bis(3-methoxy-4,1-phenylene))bis(piperazine-4,1-diyl))diethanone Parent CAS No.[1472795-20-2] |
| 产品资料 |
